Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Jodi M CarterMatthew P Goetz

Abstract

Programmed death ligand 1 [PD-(L)1]-targeted therapies have shown modest survival benefit in triple-negative breast cancer (TNBC). PD-L1+ microenvironments in TNBC are not well characterized and may inform combinatorial immune therapies. Herein, we characterized clinicopathologic features, RNA-based immune signatures, and spatially defined protein-based tumor-immune microenvironments (TIME) in early-stage PD-L1+ and PD-L1- TNBC. From a large cohort of chemotherapy-naïve TNBC, clinicopathologic features, deconvoluted RNA immune signatures, and intraepithelial and stromal TIME (Nanostring GeoMX) were identified in subsets of PD-L1+ and PD-L1- TNBC, as defined by FDA-approved PD-L1 companion assays. 228 of 499 (46%) TNBC were PD-L1+ (SP142: ≥1% immune cells-positive). Using PD-L1 22C3, 46% had combined positive score (CPS) ≥ 1 and 16% had CPS ≥10. PD-L1+ TNBC were higher grade with higher tumor-infiltrating lymphocytes (TIL; P < 0.05). PD-L1 was not associated with improved survival following adjustment for TILs and other variables. RNA profiles of PD-L1+ TNBC had increased dendritic cell, macrophage, and T/B cell subset features; and decreased myeloid-derived suppressor cells. PD-L1+ stromal and intraepithelial TIMEs were highly ...Continue Reading

References

Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Isabelle TreilleuxSerge Lebecque
Oct 30, 2012·Trends in Immunology·David H Munn, Andrew L Mellor
Jan 31, 2013·BMC Research Notes·Douglas W MahoneyJeanette E Eckel-Passow
Jun 29, 2014·BMC Bioinformatics·Krishna R KalariJean-Pierre A Kocher
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
Apr 22, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H R AliC Caldas
Jul 13, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ashley OrillionRoberto Pili
Sep 16, 2017·Breast Cancer Research and Treatment·Roberto A Leon-FerreMatthew P Goetz
Apr 11, 2018·Cancer Cell·Robert H Vonderheide
May 29, 2018·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Erik A DillAnne M Mills
Jul 20, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Douglas B JohnsonNaveen Dakappagari
Oct 23, 2018·The New England Journal of Medicine·Peter SchmidUNKNOWN IMpassion130 Trial Investigators
Feb 17, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kyung Hae JungS Lindsey Davis
Mar 7, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yi XiaoUNKNOWN AME Breast Cancer Collaborative Group
Jun 14, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria I TokiDavid L Rimm
Feb 27, 2020·The New England Journal of Medicine·Peter SchmidUNKNOWN KEYNOTE-522 Investigators
Mar 28, 2020·Proceedings of the National Academy of Sciences of the United States of America·Alexander H MorrisonRobert H Vonderheide
Apr 7, 2020·Laboratory Investigation; a Journal of Technical Methods and Pathology·Swati GuptaDavid L Rimm
Apr 18, 2020·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Emily S ReisenbichlerDavid L Rimm
May 13, 2020·Nature Biotechnology·Christopher R MerrittJoseph M Beechem
Jul 3, 2020·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Raza Syed HodaHannah Yong Wen
Jul 28, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fahad Shabbir AhmedDavid L Rimm
Aug 28, 2020·Frontiers in Oncology·María G C Navarrete-BernalLeticia Rocha-Zavaleta

❮ Previous
Next ❯

Citations

Aug 15, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·W Fraser Symmans

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.